drugset / Trial / NCT01760473
Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone
RandomizedCrossoverDouble-blindBasic science
Summary
The study is designed to compare the abuse liabilities of intranasal buprenorphine and buprenorphine/naloxone in individuals who are physically dependent on sublingual buprenorphine. The investigators hypothesize that the abuse liability of buprenorphine/naloxone is lower than that of buprenorphine alone.
Timeline
- Start
- 2009-05
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buprenorphine | Other / unclassified | 8 mg | Intranasal |
| Subject | Buprenorphine | Other / unclassified | 16 mg | Intranasal |
| Subject | Diacetylmorphine | Small molecule | 24 mg | Intranasal |
| Subject | Naloxone | Small molecule | 2 mg | Intranasal |
| Subject | Naloxone | Small molecule | 4 mg | Intranasal |
| Subject | Naloxone | Small molecule | 8 mg | Intranasal |
| Subject | Naloxone | Small molecule | 16 mg | Intranasal |